Intranasal H5N1 Vaccine Shows Broad Immune Response in Phase I Trial
Key Insights
University of Maryland researchers reported encouraging Phase I trial results for an experimental intranasal H5N1 (search) vaccine that triggered broad immune responses against multiple bird flu (search) strains.
The NanoVax H5 intranasal vaccine (search) demonstrated successful mucosal priming and was safe and well-tolerated in 40 healthy adult volunteers over six months.
Participants receiving the adjuvanted vaccine showed strong immune activity including higher protective antibodies, more memory immune cells, and better ability to kill infected cells.
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (search) (CVD) have reported encouraging results from a Phase I clinical trial of an experimental intranasal vaccine against H5N1 (search) "bird flu (search)." The study, published in Nature Communications, demonstrates the vaccine's ability to trigger broad immune responses against multiple strains of the virus, highlighting the potential of mucosal immunization strategies for pandemic preparedness.
Novel Approach to Influenza Prevention
The intranasal delivery method represents a significant departure from current influenza (search) vaccines, which are administered intramuscularly and primarily induce systemic immune responses. While traditional vaccines protect against symptomatic illness when well-matched to circulating strains, they may be less effective at preventing person-to-person transmission.
"The spread of H5N1 (search) influenza (search) in animals with spillover into human populations globally highlights the critical need for effective countermeasures to protect our communities from this and other pathogens with pandemic potential," said study corresponding author Justin Ortiz, MD, MS, Professor of Medicine at the University of Maryland School of Medicine and vaccine researcher at CVD.
Mucosal vaccines, delivered intranasally, aim to stimulate immunity at the site of infection, offering a promising approach to reduce transmission by targeting the respiratory tract where influenza (search) viruses typically enter and replicate.
Trial Design and Safety Profile
The randomized, controlled trial enrolled 40 healthy adult volunteers who were randomly assigned to receive different doses of an H5 flu vaccine formulated with BlueWillow (search)'s NanoVax® W805EC adjuvant (search). Control groups received either a placebo or a high-dose of the H5 vaccine without the adjuvant. Six months later, all volunteers received an intramuscular H5 flu booster.
The NanoVax H5 intranasal vaccine (search) was found to be safe and well-tolerated throughout the study period. Importantly, only participants who received the adjuvanted nasal vaccine showed strong immune "priming," meaning their immune systems were activated and ready to respond when later given a single dose of an intramuscular H5 flu shot.
Broad Immune Response Achieved
Even without a booster, the NanoVax H5 intranasal vaccine (search) triggered both mucosal and systemic immune defenses—something other intranasal recombinant H5 flu vaccines have not achieved in clinical trials. This dual response represents a significant advancement in vaccine development.
"The vaccine also helped the immune system recognize multiple versions of the H5N1 (search) virus, which is key because there are different versions of the virus and they change over time," said study co-lead author Meagan E. Deming, MD, PhD, Assistant Professor of Medicine at UMSOM.
Specifically, volunteers who received the adjuvanted H5 vaccine demonstrated strong immune activity including higher levels of protective antibodies (IgG and IgA), more memory immune cells, and better ability to kill infected cells. The use of the adjuvant also suggests this approach might allow for lower vaccine doses, potentially making current vaccine stocks available to more people during an outbreak.
Clinical Significance and Future Implications
"These findings demonstrate successful mucosal priming and the potential for broad cross-clade immunity," said study co-lead author Franklin R. Toapanta, MD, PhD, Associate Professor of Medicine at UMSOM. "The intranasal vaccine's ability to elicit mucosal and cellular immune responses, coupled with strong antibody-dependent cell cytotoxicity, underscores its promise as part of next-generation influenza (search) prevention strategies."
The research aligns with global public health priorities to develop vaccines that reduce transmission and provide broader protection against emerging influenza (search) strains. According to Mark T. Gladwin, MD, Dean of the University of Maryland School of Medicine, the study also highlights the need for further research into mucosal immune biomarkers and alternative immune correlates of protection, which may accelerate development of intranasal influenza vaccines.
The study was funded by a grant from the National Institutes of Allergy and Infectious Diseases (search) (U01AI148081). Further research will be required to confirm these initial findings and evaluate efficacy in larger populations as the vaccine advances through clinical development.